Drugs & Aging

, Volume 23, Issue 12, pp 997–1001 | Cite as

Intravenous Ibandronate in the Treatment of Osteoporosis

Profile Report
Adis Profile Report
  • 22 Downloads

Keywords

Bone Mineral Density Osteoporosis Bisphosphonates Alendronate Risedronate 

References

  1. 1.
    Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66(12): 1593–601PubMedCrossRefGoogle Scholar
  2. 2.
    Reginster J-Y. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  3. 3.
    Compston J. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  4. 4.
    Adami S. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3CrossRefGoogle Scholar
  5. 5.
    Roche Products Limited. Bonviva 3mg/3ml solution for injection in pre-filled syringe: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Apr 26]
  6. 6.
    Roche Laboratories Inc. Boniva® (ibandronate sodium) injection: package insert (US) [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Jul 25]
  7. 7.
    Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. June 2003 (updated Apr 2004) [online]. Available from URL: http://www.sign.ac.uk [Accessed 2006 Jun 12]
  8. 8.
    The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13(3): 340–67CrossRefGoogle Scholar
  9. 9.
    Cranney A. Treatment of postmenopausal osteoporosis: choice of treatment depends on efficacy, individual risk profile, and side effects. BMJ 2003; 327: 355–6PubMedCrossRefGoogle Scholar
  10. 10.
    Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005; 4(2): 115–25PubMedCrossRefGoogle Scholar
  11. 11.
    Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9CrossRefGoogle Scholar
  12. 12.
    Roche Products Limited. Bonviva 150mg film-coated tablets: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Jun 12]
  13. 13.
    Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103(4): 298–307PubMedCrossRefGoogle Scholar
  14. 14.
    Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34(5): 881–9PubMedCrossRefGoogle Scholar
  15. 15.
    Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34(5): 890–9PubMedCrossRefGoogle Scholar
  16. 16.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62(10): 969–75PubMedCrossRefGoogle Scholar
  17. 17.
    Delmas PD, Adami S, Strugala CSJA, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis Rheum 2006; 54(6): 1838–46PubMedCrossRefGoogle Scholar
  18. 18.
    Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract no. L8 plus poster]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12–17; San Diego (CA)Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, AucklandNew Zealand
  2. 2.Editorial office of Wolters Kluwer HealthConshohockenUSA

Personalised recommendations